These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

57 related items for PubMed ID: 16472706

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T, Gridelli C, Ciardiello F.
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [Abstract] [Full Text] [Related]

  • 5. Use of novel second-line targeted therapies in non-small cell lung cancer.
    Massarelli E, Herbst RS.
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
    [Abstract] [Full Text] [Related]

  • 6. Second-line treatment options in advanced non-small cell lung cancer: current status.
    Cullen M.
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S3-8. PubMed ID: 16472703
    [Abstract] [Full Text] [Related]

  • 7. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.
    Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4441s-4445s. PubMed ID: 16857825
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
    Johnson DH.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4451s-4457s. PubMed ID: 16857827
    [Abstract] [Full Text] [Related]

  • 10. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA, Johnson BE.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [Abstract] [Full Text] [Related]

  • 11. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J.
    J Natl Compr Canc Netw; 2003 Jan 15; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA, Thatcher N.
    Oncologist; 2008 Jan 15; 13 Suppl 1():1-4. PubMed ID: 18263768
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA, Thatcher N.
    Oncologist; 2008 Jan 15; 13 Suppl 1():37-46. PubMed ID: 18263773
    [Abstract] [Full Text] [Related]

  • 16. What phase III trials are needed to improve the treatment of advanced non-small-cell lung cancer?
    Saijo N.
    Nat Clin Pract Oncol; 2005 Jun 15; 2(6):275. PubMed ID: 16264964
    [No Abstract] [Full Text] [Related]

  • 17. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR, Dragnev KH.
    Oncologist; 2005 Jan 15; 10(1):22-33. PubMed ID: 15632250
    [Abstract] [Full Text] [Related]

  • 18. [Chemotherapy in lung carcinoma].
    Egger T, Cerny T.
    Ther Umsch; 1994 Apr 15; 51(4):267-71. PubMed ID: 7514814
    [Abstract] [Full Text] [Related]

  • 19. [Second-line chemotherapy in non-small-cell lung cancer].
    Schütte W.
    Rev Pneumol Clin; 2004 Nov 15; 60(5 Pt 3):4S13-4S16. PubMed ID: 15687987
    [No Abstract] [Full Text] [Related]

  • 20. Second-line for small cell lung cancer: how-to-do-it?
    Postmus PE.
    Lung Cancer; 2005 May 15; 48(2):263-5. PubMed ID: 15829327
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.